AnaptysBio, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ANAB Nasdaq 2836 www.anaptysbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AnaptysBio, Inc.

Anaptys Announces Participation in September Investor Conferences - Aug 29th, 2024 1:15 pm
Why AnaptysBio Was Such a Healthy Stock This Week - Aug 23rd, 2024 11:26 am
AnaptysBio Surges After Sanofi Takes A Stake In $100 Million Offering - Aug 14th, 2024 8:11 pm
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering - Aug 14th, 2024 9:00 am
Investors in AnaptysBio (NASDAQ:ANAB) have seen respectable returns of 74% over the past year - Aug 11th, 2024 1:03 pm
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Misses Revenue Estimates - Aug 5th, 2024 9:55 pm
Illumina (ILMN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Jul 30th, 2024 2:01 pm
AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release - Jul 29th, 2024 2:00 pm
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst - Jul 22nd, 2024 6:53 pm
Is HCA Healthcare (HCA) Stock Outpacing Its Medical Peers This Year? - Jul 22nd, 2024 1:40 pm
Repligen (RGEN) Soars 4.4%: Is Further Upside Left in the Stock? - Jun 24th, 2024 11:33 am
Industry Analysts Just Upgraded Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts By 16% - May 22nd, 2024 10:43 am
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates - May 9th, 2024 9:45 pm
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update - May 9th, 2024 8:15 pm
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) - May 9th, 2024 8:10 pm
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties - May 9th, 2024 8:05 pm
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - May 2nd, 2024 2:01 pm
AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock? - May 1st, 2024 8:51 am
Actym Therapeutics Appoints Thomas Smart as CEO - Apr 24th, 2024 1:00 pm
BTIG Research Predicts Over 118% Rally for These 3 Stocks - Apr 15th, 2024 6:19 pm